Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-cash Items: 2013-2024

Historic Non-cash Items for Ptc Therapeutics (PTCT) over the last 8 years, with Dec 2024 value amounting to $6.8 million.

  • Ptc Therapeutics' Non-cash Items fell 15.55% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 15.55%. This contributed to the annual value of $6.8 million for FY2024, which is 22.34% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Non-cash Items is $6.8 million, which was down 22.34% from $8.8 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Non-cash Items ranged from a high of $38.3 million in FY2022 and a low of $4.2 million during FY2020.
  • Over the past 3 years, Ptc Therapeutics' median Non-cash Items value was $8.8 million (recorded in 2023), while the average stood at $18.0 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Non-cash Items soared by 543.30% in 2022, and later crashed by 77.00% in 2023.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Non-cash Items stood at $4.2 million in 2020, then surged by 40.23% to $6.0 million in 2021, then skyrocketed by 543.30% to $38.3 million in 2022, then tumbled by 77.00% to $8.8 million in 2023, then decreased by 22.34% to $6.8 million in 2024.